Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • MSA
    • Parkinson’s Disease
    • Posters & Publications
  • News & Media
    • Press Releases
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

In The News

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Sep 12, 2018

Stockhouse - The Key to Unlocking Alzheimers Treatment?

Sep 12, 2018

Global Business Report – Interview with Eugene Williams Executive Chairman, ProMIS

Aug 27, 2018

ProMIS’ PMN310 Shows Improved Safety Profile, Specificity Compared to Similar Alzheimer’s Candidates

Jul 9, 2018

Why Hope Endures For An Alzheimer's Treatment — And Biogen Could Be First

Jun 21, 2018

ProMIS Trial Offers Hope For Alzheimer's Patients

Apr 19, 2018

Biocentury – Promis Identifies New Beta Amyloid Epitope To Treat AD

Mar 7, 2018

As Vtv data nearing in April, Promis AD bid a contender

Jan 13, 2018

ProMIS Alzheimer’s Therapy Attacks Only Harmful Brain Protein, Unlike Other Treatments, Study Finds

Nov 29, 2017

Routes are opening up potentially to prevent or reverse damage that leads to the disease

Nov 28, 2017

New Alzheimer’s disease candidate selectively targets toxic AβO

rss_feed RSS
  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy